Literature DB >> 10438359

Vaccination with pertussis toxin alters the antibody response to simultaneous respiratory syncytial virus challenge.

J E Fischer1, T R Johnson, R S Peebles, B S Graham.   

Abstract

Many bacterial toxins, including pertussis toxin (PT), exert potent adjuvant effects on antibody synthesis to coadministered antigens. In these studies, we examined whether locally or peripherally administered PT similarly altered the antibody isotype selection to replicating virus after intranasal (inl) challenge. Mice primed intramuscularly with PT and inl with respiratory syncytial virus (RSV) produced RSV-specific antibodies of the IgG2a isotype at a level similar to that of unprimed controls, with some increase in IgG1 production. Mice primed inl with both PT and RSV showed elevated RSV-specific IgG1, increased serum IgE levels, and increased interleukin (IL)-4 in lung supernatants. Splenocytes from these animals produced increased IL-4 when stimulated in vitro with RSV or PT antigens after infection. These results suggest that PT can influence the local production of IL-4 to alter the humoral and cellular immune responses to viral infection as well as to coadministered antigens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438359     DOI: 10.1086/314947

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  2 in total

1.  Effects of a diphtheria-tetanus-acellular pertussis vaccine on immune responses in murine local lymph node and lung allergy models.

Authors:  Rob J Vandebriel; Eric R Gremmer; Michiel van Hartskamp; Jan A M A Dormans; Frits R Mooi
Journal:  Clin Vaccine Immunol       Date:  2007-01-03

2.  Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis.

Authors:  Hye Suk Hwang; Young-Man Kwon; Jong Seok Lee; Si-Eun Yoo; Yu-Na Lee; Eun-Ju Ko; Min-Chul Kim; Min-Kyoung Cho; Young-Tae Lee; Yu-Jin Jung; Ji-Yun Lee; Jian-Dong Li; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2014-08-07       Impact factor: 5.970

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.